Rasagiline’s domestic availability and purchase channels

Rasagiline (Rasagiline) is a selective monoamine oxidase-B (MAO-B) inhibitor. It is mainly used for the monotherapy of Parkinson's disease (PD) or in combination with levodopa to improve motor symptoms and reduce "on-off" fluctuations. Domestically, rasagiline has been officially approved and successfully launched on the market, providing patients with Parkinson's disease with more treatment options. Drugs inhibit dopamine metabolism and increase dopamine levels in the brain, thereby improving motor function and quality of life.

In the domestic market, rasagiline has been included in the national medical insurance directory, and patients can purchase it through medical insurance reimbursement in regular hospitals or pharmacies. Specific medical insurance reimbursement prices and rates vary depending on region and hospital policies. Patients are advised to consult with local hospitals or pharmacies before purchasing to obtain the latest cost information and reimbursement details. The implementation of this policy enables patients taking long-term medication to reduce their financial burden and improve medication compliance.

In overseas markets, the original drug of rasagiline is on the market in Türkiye, with a price of approximately RMB 1,000. In contrast, the price of rasagiline available in China is relatively affordable, ranging from a few hundred yuan to more than a thousand yuan. For some patients, domestic price advantages are obvious, and long-term treatment costs are further reduced through medical insurance reimbursement, making it easier for patients to obtain continuous medication support.

In addition, there is an Indian version of rasagiline generic drug on the overseas market, the price of which is only more than 300 yuan, which is about half the price of the original drug. Although lower in price, generic drugs are essentially identical in ingredients and efficacy to brand-name drugs, providing patients with an affordable alternative. Overall, the domestic launch and medical insurance coverage of rasagiline enable patients to ensure the efficacy while also taking into account the financial burden, while the existence of overseas generic drugs provides more flexible medication pathways.

Reference link:https://www.drugs.com